Public Health Ethics Advance Access originally published online on May 21, 2008
Public Health Ethics 2008 1(2):104-109; doi:10.1093/phe/phn020
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
The Author 2008. Published by Oxford University Press. Available online at www.phe.oxfordjournals.org
Challenges to the Successful Introduction of Biotechnologies in Developing Countries
UNICEF
* Corresponding author: Stephen W. Jarrett, Principal Adviser, UNICEF, 3 United Nations Plaza, New York, NY 10017, USA. Tel.: +1 212 326 7246; Fax: +1 212 326 7477; Email: sjarrett@unicef.org
| The first 150 words of the full text of this article appear below. |
The right to health means biotechnologies should be readily available to all, rich and poor alike. In the case of vaccines, however, there is a significant divergence in availability between rich and poor countries, both in number and types of vaccines. Reducing this divergence is a clear ethical challenge, so populations everywhere, especially children, are equally protected from a range of killer diseases, and mortality rates in children can be significantly reduced. Incentives must be available for industry to meet the full vaccine needs of poor countries. Poor countries themselves should have access to sufficient resources to establish a reliable and predictable demand for a wide range of relevant vaccines, both new and old.
There is a moral imperative to ensure that everyone everywhere has access to the biotechnologies they need to achieve and sustain a high level of health. This is fully consistent with health being a fundamental right,
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  T. Pogge Access to Medicines Public Health Ethics, July 1, 2008; 1(2): 73 - 82. [Abstract] [Full Text] [PDF]
|
|